NCT03046771 is a NA clinical trial of Transport PLUS group in Fall, Accidental, sponsored by Icahn School of Medicine at Mount Sinai.

Who is sponsoring NCT03046771?

NCT03046771 is sponsored by Icahn School of Medicine at Mount Sinai.

What drugs are being tested in NCT03046771?

Interventions in NCT03046771: Transport PLUS group.

What condition does NCT03046771 study?

NCT03046771 studies Fall, Accidental, Fall, Hospital Readmission, Emergency Medical Services.

Is NCT03046771 still recruiting?

NCT03046771 is currently completed. Last updated 5 February 2020.

Last reviewed 2020-02-05 · How we verify

NCT03046771

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transport PLUS Intervention

Completed NA Last updated 5 February 2020

What this trial tests

NA trial testing Transport PLUS group in Fall, Accidental in 58 participants. Completed in 30 May 2019.

Timeline

19 January 2017

Primary endpoint
23 August 2018

30 May 2019

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	58
Start date	19 January 2017
Primary completion	23 August 2018
Estimated completion	30 May 2019
Sites	1 location across United States

Drugs / interventions tested

Transport PLUS group

Conditions studied

Fall, Accidental — all drugs for Fall, Accidental →
Fall — all drugs for Fall →
Hospital Readmission — all drugs for Hospital Readmission →
Emergency Medical Services — all drugs for Emergency Medical Services →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

18 and older, any sex, with Fall, Accidental or Fall. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypothesis: 'Transport PLUS,' a low cost, easily generalizable intervention performed by Emergency Medical Technicians while transporting a patient home from the hospital, can improve transitions of care and improve patient safety following hospitalization as measured by decreased rates of falls and reduced rates of return to the hospital.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03046771 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 5 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03046771.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing